21
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Children develop robust and sustained cross-reactive spike-specific immune responses to SARS-CoV-2 infection

      research-article
      1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 1 , 2 , 2 , 1 , 1 , 1 , 1 , 3 , 4 , 3 , 5 , 6 , 7 , 8 , 9 , 10 , 9 , 3 , 3 , 3 , 3 , 11 , 11 , 12 , 12 , 12 , 2 , 2 , 2 , 2 , 13 , 3 , 3 , 3 , 3 , 1 , 1 , , 3 , 14
      Nature Immunology
      Nature Publishing Group US
      Adaptive immunity, Infectious diseases, Viral infection, SARS-CoV-2

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          SARS-CoV-2 infection is generally mild or asymptomatic in children but a biological basis for this outcome is unclear. Here we compare antibody and cellular immunity in children (aged 3–11 years) and adults. Antibody responses against spike protein were high in children and seroconversion boosted responses against seasonal Beta-coronaviruses through cross-recognition of the S2 domain. Neutralization of viral variants was comparable between children and adults. Spike-specific T cell responses were more than twice as high in children and were also detected in many seronegative children, indicating pre-existing cross-reactive responses to seasonal coronaviruses. Importantly, children retained antibody and cellular responses 6 months after infection, whereas relative waning occurred in adults. Spike-specific responses were also broadly stable beyond 12 months. Therefore, children generate robust, cross-reactive and sustained immune responses to SARS-CoV-2 with focused specificity for the spike protein. These findings provide insight into the relative clinical protection that occurs in most children and might help to guide the design of pediatric vaccination regimens.

          Abstract

          SARS-CoV-2 infection is milder in children, but direct comparison with adults is rare. Here the authors show that immune responses are higher in children, retained for 12 months or longer and can neutralize Alpha, Beta and Delta variants.

          Related collections

          Most cited references38

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

          Understanding immune memory to SARS-CoV-2 is critical for improving diagnostics and vaccines, and for assessing the likely future course of the COVID-19 pandemic. We analyzed multiple compartments of circulating immune memory to SARS-CoV-2 in 254 samples from 188 COVID-19 cases, including 43 samples at ≥ 6 months post-infection. IgG to the Spike protein was relatively stable over 6+ months. Spike-specific memory B cells were more abundant at 6 months than at 1 month post symptom onset. SARS-CoV-2-specific CD4+ T cells and CD8+ T cells declined with a half-life of 3-5 months. By studying antibody, memory B cell, CD4+ T cell, and CD8+ T cell memory to SARS-CoV-2 in an integrated manner, we observed that each component of SARS-CoV-2 immune memory exhibited distinct kinetics.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Human neutralizing antibodies elicited by SARS-CoV-2 infection

            The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents a global health emergency that is in urgent need of intervention1-3. The entry of SARS-CoV-2 into its target cells depends on binding between the receptor-binding domain (RBD) of the viral spike protein and its cellular receptor, angiotensin-converting enzyme 2 (ACE2)2,4-6. Here we report the isolation and characterization of 206 RBD-specific monoclonal antibodies derived from single B cells from 8 individuals infected with SARS-CoV-2. We identified antibodies that potently neutralize SARS-CoV-2; this activity correlates with competition with ACE2 for binding to RBD. Unexpectedly, the anti-SARS-CoV-2 antibodies and the infected plasma did not cross-react with the RBDs of SARS-CoV or Middle East respiratory syndrome-related coronavirus (MERS-CoV), although there was substantial plasma cross-reactivity to their trimeric spike proteins. Analysis of the crystal structure of RBD-bound antibody revealed that steric hindrance inhibits viral engagement with ACE2, thereby blocking viral entry. These findings suggest that anti-RBD antibodies are largely viral-species-specific inhibitors. The antibodies identified here may be candidates for development of clinical interventions against SARS-CoV-2.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

              Preexisting immune response to SARS-CoV-2 Robust T cell responses to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus occur in most individuals with coronavirus disease 2019 (COVID-19). Several studies have reported that some people who have not been exposed to SARS-CoV-2 have preexisting reactivity to SARS-CoV-2 sequences. The immunological mechanisms underlying this preexisting reactivity are not clear, but previous exposure to widely circulating common cold coronaviruses might be involved. Mateus et al. found that the preexisting reactivity against SARS-CoV-2 comes from memory T cells and that cross-reactive T cells can specifically recognize a SARS-CoV-2 epitope as well as the homologous epitope from a common cold coronavirus. These findings underline the importance of determining the impacts of preexisting immune memory in COVID-19 disease severity. Science, this issue p. 89
                Bookmark

                Author and article information

                Contributors
                p.moss@bham.ac.uk
                Journal
                Nat Immunol
                Nat Immunol
                Nature Immunology
                Nature Publishing Group US (New York )
                1529-2908
                1529-2916
                22 December 2021
                22 December 2021
                2022
                : 23
                : 1
                : 40-49
                Affiliations
                [1 ]GRID grid.6572.6, ISNI 0000 0004 1936 7486, Institute of Immunology & Immunotherapy, College of Medical and Dental Sciences, , University of Birmingham, ; Birmingham, UK
                [2 ]GRID grid.301713.7, ISNI 0000 0004 0393 3981, MRC-University of Glasgow Centre for Virus Research, ; Glasgow, UK
                [3 ]GRID grid.271308.f, ISNI 0000 0004 5909 016X, Public Health England, 61 Colindale Avenue, ; London, UK
                [4 ]GRID grid.450709.f, ISNI 0000 0004 0426 7183, East London NHS Foundation Trust, ; London, UK
                [5 ]GRID grid.508499.9, University Hospitals of Derby and Burton NHS Foundation Trust, ; Derby, UK
                [6 ]GRID grid.498924.a, Manchester University NHS Foundation Trust, ; Manchester, UK
                [7 ]GRID grid.439530.8, ISNI 0000 0004 0446 956X, Birmingham Community Healthcare NHS Trust, ; Aston, UK
                [8 ]GRID grid.6572.6, ISNI 0000 0004 1936 7486, Institute of Applied Health Research, College of Medical and Dental Sciences, , University of Birmingham, ; Birmingham, UK
                [9 ]GRID grid.410556.3, ISNI 0000 0001 0440 1440, Oxford University Hospitals NHS Foundation Trust, ; Oxford, UK
                [10 ]GRID grid.4991.5, ISNI 0000 0004 1936 8948, University of Oxford, Wellington Square, ; Oxford, UK
                [11 ]GRID grid.419319.7, ISNI 0000 0004 0641 2823, Public Health England, Manchester Royal Infirmary, ; Manchester, UK
                [12 ]GRID grid.418449.4, ISNI 0000 0004 0379 5398, Bradford Institute for Health Research, Bradford Teaching Hospitals NHS Foundation Trust, ; Bradford, UK
                [13 ]GRID grid.7445.2, ISNI 0000 0001 2113 8111, Department of Infectious Disease, Imperial College, ; London, UK
                [14 ]GRID grid.264200.2, ISNI 0000 0000 8546 682X, Paediatric Infectious Diseases Research Group, St. George’s University of London, ; London, UK
                Author information
                http://orcid.org/0000-0002-1909-7047
                http://orcid.org/0000-0002-2872-4794
                http://orcid.org/0000-0002-8380-8122
                http://orcid.org/0000-0001-9496-5660
                http://orcid.org/0000-0002-4807-2797
                http://orcid.org/0000-0001-9268-0581
                http://orcid.org/0000-0002-0691-6568
                http://orcid.org/0000-0002-5935-6154
                http://orcid.org/0000-0003-1482-0889
                http://orcid.org/0000-0001-8912-3266
                http://orcid.org/0000-0003-2874-4290
                http://orcid.org/0000-0002-7156-7640
                http://orcid.org/0000-0002-8341-465X
                http://orcid.org/0000-0002-6895-1967
                Article
                1089
                10.1038/s41590-021-01089-8
                8709786
                34937928
                fcc6cbef-9a7e-4aff-a2a4-ee40a10d7c28
                © The Author(s) 2021

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 28 April 2021
                : 3 November 2021
                Funding
                Funded by: Partly funded by UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC)
                Funded by: FundRef https://doi.org/10.13039/501100000265, RCUK | Medical Research Council (MRC);
                Award ID: MC UU 1201412
                Award Recipient :
                Funded by: G2P-UK National Virology Consortium (MR/W005611/1) funded by the UKRI
                Categories
                Article
                Custom metadata
                © The Author(s), under exclusive licence to Springer Nature America, Inc. 2022

                Immunology
                adaptive immunity,infectious diseases,viral infection,sars-cov-2
                Immunology
                adaptive immunity, infectious diseases, viral infection, sars-cov-2

                Comments

                Comment on this article